Navigation Links
Early-stage, HER2-positive breast cancer patients at increased risk of recurrence
Date:11/2/2009

HOUSTON - Early-stage breast cancer patients with HER2 positive tumors one centimeter or smaller are at significant risk of recurrence of their disease, compared to those with early-stage disease who do not express the aggressive protein, according to a study led by researchers at The University of Texas M. D. Anderson Cancer Center.

The findings, published today online in the Journal of Clinical Oncology, is the first large study to analyze this cohort and represents a shift in the way women with early-stage HER2 positive breast cancer should be assessed for risk of recurrence and considered for treatment, said the study's senior author, Ana M. Gonzalez-Angulo, M.D, associate professor in M. D. Anderson's Departments of Breast Medical Oncology and Systems Biology.

The research was first presented at the CRTC-AACR San Antonio Breast Cancer Symposium in December, 2008.

Herceptin, also known as trastuzumab, was approved for use in 1998 for women whose advanced breast cancer expresses Human Epidermal growth factor Receptor 2, or HER2. Approximately 15-20 percent of breast cancer cells produce an excess amount of the HER2 growth protein on their surface, which makes the cancer more aggressive. Herceptin is a monoclonal antibody that latches on to these proteins and inhibits tumor growth.

"This study represents a current debate within clinical practice - the risk of recurrence for early-stage breast cancer patients with HER2 positive tumors one centimeter or smaller," said Gonzalez-Angulo. "Our findings show that women with early stage HER2 positive breast cancer have a 23 percent chance of recurrence. In contrast, the five-year survival rate of all women with such early-stage breast cancer is more than 90 percent.

"The findings indicate that physicians need to consider offering these women Herceptin-based therapy in the post-operative, or adjuvant setting," Gonzalez-Angulo continued.

Current guid
'/>"/>

Contact: Laura Sussman
lsussman@mdanderson.org
713-745-2457
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert  

Page: 1 2 3

Related medicine news :

1. If Herceptin is Approved in Combination With Other Emerging Therapies it Will be in a Position to Retain Patient Share From Tykerb/Tyverb for the Treatment of HER2-Positive Breast Cancer
2. Early stage, HER2-positive breast cancer patients at increased risk of recurrence
3. Anthracyclines improve survival in HER2-positive breast cancer patients
4. Adapting space-industry technology to treat breast cancer
5. Company C Donates $40,000 To Fight Breast Cancer
6. Metropolitan Chicago Breast Cancer Task Force Announced Members of Chicago Breast Cancer Quality Consortium
7. 4th Annual Henry Schein Think Pink, Practice Pink Campaign Coincides With Breast Cancer Awareness Month
8. Cancer Centers of North Carolina Offers New 5-Day Breast Cancer Therapy
9. Gastroenterologists explore relationship between bacteria in the gut and breast cancer
10. Meditation May Reduce Stress in Breast Cancer Patients
11. Beaumont, U-M Open Study of Drug for Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Early-stage, HER2-positive breast cancer patients at increased risk of recurrence
(Date:7/30/2014)... York, New York (PRWEB) July 30, 2014 ... from uncontrollable brain bleeding has filed a Xarelto lawsuit ... by the blood thinner, Bernstein Liebhard LLP reports. According ... Court for the District of Vermont on July 25th, ... days when he suffered an irreversible brain bleed that ...
(Date:7/30/2014)... 2014 Imprivata ® (NYSE: ... and secure communications solutions for the healthcare industry, ... the most widely selected single sign-on (SSO) solution ... electronic medical records (EMR) systems with a 51 ... percent in the last 12 months), according to ...
(Date:7/30/2014)... Visitors to our region recognize how special it ... protection. Bob Kiesendahl, one of the owners of Woodloch ... Conservancy for donations collected through participation in the Green ... fast, as visitors welcome the opportunity to invest in ... The Kiesendahl family has owned Woodloch Resort for multiple ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Hamilton ... opening of its new Carmel office on July 30th. ... will finally be moving to the state-of-the-art suite, located ... and innovative space will allow for one-on-one patient comfort, ... surgery experience. , Dr. Hamilton’s new office-suite will ...
(Date:7/30/2014)... (HealthDay News) -- Some obese people have a genetic ... in their brains when they see food, researchers report. ... triggers feelings of pleasure and gratification at the sight ... designed to prevent overeating, the scientists suggested. More ... typically caused by a combination of overeating, a ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 3Health News:Imprivata Achieves 51 Percent Single Sign-on Market Share Amongst U.S. Hospitals Using McKesson Paragon or Horizon EMR Systems, According to HIMSS Analytics 2Health News:Pocono Mountain Resort Guests Contribute Over $8500 to Protect Land in 6 Short Months 2Health News:Hamilton Facial Plastic Surgery Opens New Carmel Office 2Health News:Gene Mutation May Make Food More Tempting 2
... Health Advocate Christy Turlington Burns will speak at the ... Health meeting at the AAP National Conference & Exhibition ... ET. Ms. Turlington Burns is the founder of Every ... to increase public awareness of and support for improved ...
... developed by the Centers for Disease Control and ... Pediatrics (AAP), will be launched at the 2011 ... Oct. 15-17. "Autism Case Training -- ... on the fundamental components of identifying, diagnosing, and ...
... New research presented this week highlights the ability ... investigate publicly available genomic data to assess biological ... prospective cancer biomarkers for further validation. The unique ... not possible by other methods, from the massive ...
... onset breast tenderness after starting combination hormone therapy may ... women who don,t experience breast tenderness, a study by ... One reason for this may be that their breasts ... was much more pronounced after initiation of estrogen and ...
... Il. -- MRI scanning could become a powerful new ... according to Loyola University Health System cardiologist Binh An ... MRI study of patients who had recently begun taking ... cholesterol drugs significantly reduced the amount of cholesterol in ...
... 14 (HealthDay News) -- One in six cellphones in Britain ... coli, likely because so many people don,t wash their hands ... The findings also suggest that many people lie about their ... of Hygiene & Tropical Medicine and Queen Mary, University of ...
Cached Medicine News:Health News:CDC to launch new autism curriculum at AAP national conference & exhibition 2Health News:Drug safety, efficacy, and potential new cancer biomarker predicted by NextBio 2Health News:Drug safety, efficacy, and potential new cancer biomarker predicted by NextBio 3Health News:Breast tenderness in women getting combo hormone therapy associated with increase in breast density 2Health News:Breast tenderness in women getting combo hormone therapy associated with increase in breast density 3Health News:MRIs could become powerful tools for monitoring cholesteral therapy 2Health News:1 in 6 Cellphones in Britain Contaminated With 'Fecal Matter' 2
(Date:7/30/2014)... ALEXANDRIA, Va. , July 30, 2014 /PRNewswire-USNewswire/ ... of Managed Care Pharmacy (AMCP) last evening expressed ... developed by the Joint Commission of Pharmacy Practitioners ... other member organizations over a two-year period to ... process for pharmacists.  "Pharmacists are ...
(Date:7/30/2014)... 30, 2014 PuraMed BioScience ® , ... over-the-counter (OTC) medicinal and healthcare products, announced today ... name along with the name,s red and yellow ... trademarked name MigraPure ®  going forward. The ... homeopathic, natural migraine pain reliever will be reintroduced ...
(Date:7/30/2014)... -- Research and Markets has announced the addition of ... report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... a lower CAGR in developed countries; however, it is expected to ... , India , and Brazil ... of the hematology analyzers and reagents market is driven by factors ...
Breaking Medicine Technology:AMCP Endorses JCPP "Pharmacists' Patient Care Process" 2PuraMed BioScience Rebrands its Natural Migraine Relief Medication, LipiGesic M 2PuraMed BioScience Rebrands its Natural Migraine Relief Medication, LipiGesic M 3Hematology Analyzers & Reagents Market - Forecasts to 2019 2
... 13, 3010 Amgen (Nasdaq: AMGN ) ... evaluating XGEVA™ (denosumab) versus placebo in 1,432 men with ... study, demonstrated that XGEVA significantly improved median bone metastasis-free ... p=0.03) compared to placebo (primary endpoint), and significantly improved ...
... Fla., Dec. 13, 2010 The creators of the innovative Pill ... toys and a much needed medication management system to pediatric ... at Broward General, in Fort Lauderdale, Florida. ... will be onsite Wednesday, December 15, from 1-3 pm distributing ...
Cached Medicine Technology:XGEVA™ (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer 2XGEVA™ (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer 3XGEVA™ (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer 4XGEVA™ (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer 5XGEVA™ (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer 6XGEVA™ (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer 7Med Time Technology, Inc. Teams up with Give A Smile, Inc. to Provide Pill Timer™ Kits and Toys to Children and Parents at the Chris Evert Children's Hospital of Broward General 2
Inquire...
... with low electroendosmosis (EEO) ... DNA/RNA applications. If separated ... be used as substrates ... and restriction endonucleases, a ...
... NuSieve 3:1 Agarose is a molecular biology grade, ... for fine resolution of small DNA, RNA, and ... enhance the speed of gel processing and blotting. ... resolution of DNA fragments up to 1,000 bp, ...
... With a very high gel ... exclusion limit, Certified megabase agarose is ... FIGE applications. The gels remain easy ... as 0.3% and allow shorter run ...
Medicine Products: